Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 1, 2016, Pages 142-149.e8

  Bateman, Eric D ^a   Goehring, Udo Michael ^b   Richard, Frank ^c   Watz, Henrik ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Takeda Pharmaceuticals International GmbH   (Switzerland)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d Member of the German Center for Lung Research   (Germany)

Author keywords

Asthma; montelukast; phosphodiesterase 4 inhibitors; roflumilast

Indexed keywords

CREATINE KINASE; LEUKOTRIENE E4; MONTELUKAST; PLACEBO; ROFLUMILAST; ACETIC ACID DERIVATIVE; AMINOPYRIDINE DERIVATIVE; ANTIASTHMATIC AGENT; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; QUINOLINE DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; ASTHMA; BRONCHITIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INFLUENZA; LARYNGITIS; LIMB PAIN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; PATIENT-REPORTED OUTCOME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE COURSE; LEUKOCYTE COUNT; MULTICENTER STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TREATMENT OUTCOME; VERY ELDERLY;

ACETATES; AGED; AGED, 80 AND OVER; AMINOPYRIDINES; ANTI-ASTHMATIC AGENTS; ASTHMA; BENZAMIDES; CYCLOPROPANES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOCYTE COUNT; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; QUINOLINES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TREATMENT OUTCOME;

EID: 84973110915     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.11.035     Document Type: Article

References (27)

1. 1 Chung, K.F., Wenzel, S.E., Brozek, J.L., Bush, A., Castro, M., Sterk, P.J., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43 (2014), 343–373.
2. 2 Global Strategy for Asthma Management and Prevention. Available at: http://www.ginasthma.org/. Accessed September 11, 2015.
3. 3 Normansell, R., Walker, S., Milan, S.J., Walters, E.H., Nair, P., Omalizumab for asthma in adults and children. Cochrane Database Syst Rev, 1, 2014, CD003559.
4. 4 Kerstjens, H.A., Engel, M., Dahl, R., Paggiaro, P., Beck, E., Vandewalker, M., et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 367 (2012), 1198–1207.
5. 5 Virchow, J.C. Jr., Prasse, A., Naya, I., Summerton, L., Harris, A., Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 162 (2000), 578–585.
6. 6 Pavord, I.D., Korn, S., Howarth, P., Bleecker, E.R., Buhl, R., Keene, O.N., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380 (2012), 651–659.
7. 7 Olin, J.T., Wechsler, M.E., Asthma: pathogenesis and novel drugs for treatment. BMJ, 349, 2014, g5517.
8. 8 Hastie, A.T., Moore, W.C., Meyers, D.A., Vestal, P.L., Li, H., Peters, S.P., et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 125 (2010), 1028–1036.
9. 9 Schudt, C., Tenor, H., Hatzelmann, A., PDE isoenzymes as targets for anti-asthma drugs. Eur Respir J 8 (1995), 1179–1183.
10. 10 Essayan, D.M., Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem Pharmacol 57 (1999), 965–973.
11. 11 van Schalkwyk, E., Strydom, K., Williams, Z., Venter, L., Leichtl, S., Schmid-Wirlitsch, C., et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 116 (2005), 292–298.
12. 12 Gauvreau, G.M., Boulet, L.P., Schmid-Wirlitsch, C., Côté, J., Duong, M., Killian, K.J., et al. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res, 12, 2011, 140.
13. 13 Grootendorst, D.C., Gauw, S.A., Verhoosel, R.M., Sterk, P.J., Hospers, J.J., Bredenbröker, D., et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62 (2007), 1081–1087.
14. 14 Timmer, W., Leclerc, V., Birraux, G., Neuhäuser, M., Hatzelmann, A., Bethke, T., et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol 42 (2002), 297–303.
15. 15 Bateman, E.D., Izquierdo, J.L., Harnest, U., Hofbauer, P., Magyar, P., Schmid-Wirlitsch, C., et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 96 (2006), 679–686.
16. 16 Calverley, P.M., Rabe, K.F., Goehring, U.M., Kristiansen, S., Fabbri, L.M., Martinez, F.J., et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374 (2009), 685–694.
17. 17 Bateman, E.D., Rabe, K.F., Calverley, P.M., Goehring, U.M., Brose, M., Bredenbröker, D., et al. Roflumilast with long-acting beta2-agonists for COPD: influence of exacerbation history. Eur Respir J 38 (2011), 553–560.
18. 18 Martinez, C., Guzman, R., Fernandez, R., Following recommendations: a challenge in occupational asthma. Arch Bronconeumol 51 (2015), 105–106.
19. 19 Miller, M.R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., et al. Standardisation of spirometry. Eur Respir J 26 (2005), 319–338.
20. 20 Juniper, E.F., O'Byrne, P.M., Guyatt, G.H., Ferrie, P.J., King, D.R., Development and validation of a questionnaire to measure asthma control. Eur Respir J 14 (1999), 902–907.
21. 21 Reddel, H.K., Taylor, D.R., Bateman, E.D., Boulet, L.P., Boushey, H.A., Busse, W.W., et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 180 (2009), 59–99.
22. 22 Pedersen, F., Holz, O., Lauer, G., Quintini, G., Kiwull-Schöne, H., Kirsten, A.M., et al. Multi-analyte profiling of inflammatory mediators in COPD sputum—the effects of processing. Cytokine 71 (2015), 401–404.
23. 23 Theron, A.J., Steel, H.C., Tintinger, G.R., Gravett, C.M., Anderson, R., Feldman, C., Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J Immunol Res, 2014, 2014, 608930.
24. 24 Bateman, E.D., Esser, D., Chirila, C., Fernandez, M., Fowler, A., Moroni-Zentgraf, P., et al. Magnitude of effect of asthma treatments on AQLQ and ACQ: systematic review and network meta-analysis. J Allergy Clin Immunol 136 (2015), 914–922.
25. 25 Szefler, S.J., Wenzel, S., Brown, R., Erzurum, S.C., Fahy, J.V., Hamilton, R.G., et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol 129:suppl (2012), S9–S23.
26. 26 Rabinovitch, N., Mauger, D.T., Reisdorph, N., Covar, R., Malka, J., Lemanske, R.F. Jr., et al. Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma. J Allergy Clin Immunol 133 (2014), 350–356.
27. 27 Bohmer, G.M., Nassr, N., Wenger, M., Hünnemeyer, A., Lahu, G., Templin, S., et al. The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions. J Clin Pharmacol 49 (2009), 389–397.